Imagen Biotech secures $40 million in Series A financing

Thursday, October 20, 2011

Imagen Biotech has secured up to $40 million in Series A financing from SV Life Sciences, Novo Ventures, and Fidelity Biosciences to pursue the identification and development of breakthrough treatments for blinding diseases with high unmet medical needs, including dry age-related macular degeneration. Matthew Feinsod, MD, an ophthalmologist who was formerly at Eyetech Pharmaceuticals and a medical officer in the FDA’s Ophthalmology Division, will lead these efforts as chief medical officer for Imagen. Additional terms will not be disclosed.

[Read More]